Overview

Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes

Status:
Completed

Trial end date:
2000-05-01

Target enrollment:

Participant gender:

Summary

This trial is conducted in Europe. The aim of this trial is to evaluate the safety profile of insulin aspart in subjects with type 1 diabetes having participated in trial ANA/DCD/035.

Phase:

Phase 3

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Insulin
Insulin Aspart
Insulin degludec, insulin aspart drug combination
Insulin, Globin Zinc
Insulin, Isophane
Insulin, Long-Acting
Isophane insulin, beef
Isophane Insulin, Human